VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 20, 2008) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, announced today that it has expanded the scope of its ongoing clinical trial evaluating the pharmacokinetics of the Company’s drug AL-108 by adding Alzheimer’s disease patients to the study.
